Anti-cytokine therapies in T1D: Concepts and strategies

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 279-285

  Nepom, Gerald T ^a   Ehlers, Mario ^b   Mandrup Poulsen, Thomas ^c,d  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b Immune Tolerance Network   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti inflammatory; Autoimmunity; Immunotherapy; Regulatory T cells

Indexed keywords

ETANERCEPT; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; PLACEBO; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TOCILIZUMAB; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; APOPTOSIS; AUTOIMMUNITY; BEHCET DISEASE; BINDING AFFINITY; CELL MEMBRANE; CELL STRESS; CHILDHOOD DISEASE; CROHN DISEASE; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; ENDOPLASMIC RETICULUM; ENHANCER REGION; FOLLOW UP; GENE DUPLICATION; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; JUVENILE RHEUMATOID ARTHRITIS; MENDELIAN RANDOMIZATION ANALYSIS; NERVE CELL PLASTICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATIC POLYMYALGIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANTI-INFLAMMATORY; AUTOIMMUNITY; DAMAGE/DANGER-ASSOCIATED MOLECULAR PATTERNS; DAMPS; EFFECTOR T CELL(S); IL-1 RECEPTOR ACCESSORY PROTEIN; IL-1 RECEPTOR ANTAGONIST; IL-1RA; IL-1RACP; IMMUNOTHERAPY; LIPOPOLYSACCHARIDE; LPS; NOD; NON-OBESE DIABETIC (MICE); REACTIVE OXYGEN SPECIES; REGULATORY T CELL(S); REGULATORY T CELLS; ROS; T1D; T2D; TEFF; THIOREDOXIN INHIBITORY PROTEIN; TLR; TOLL-LIKE RECEPTOR; TREG; TXNIP; TYPE 1 DIABETES; TYPE 2 DIABETES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKIN-6; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887017618     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.003     Document Type: Review

References (60)

1. Ablamunits V., Henegariu O., Hansen J.B., Opare-Addo L., Preston-Hurlburt P., Santamaria P., Mandrup-Poulsen T., Herold K.C. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012, 61:145-154.
2. Arif S., Moore F., Marks K., Bouckenooghe T., Dayan C.M., Planas R., Vives-Pi M., Powrie J., Tree T., Marchetti P., Huang G.C., Gurzov E.N., Pujol-Borrell R., Eizirik D.L., Peakman M. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011, 60:2112-2119.
3. Bending D., De la Pena H., Veldhoen M., Phillips J.M., Uyttenhove C., Stockinger B., Cooke A. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 2009, 119:565-572.
4. Benson J.M., Peritt D., Scallon B.J., Heavner G.A., Shealy D.J., Giles-Komar J.M., Mascelli M.A. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011, 3:535-545.
5. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
6. Bradshaw E.M., Raddassi K., Elyaman W., Orban T., Gottlieb P.A., Kent S.C., Hafler D.A. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 2009, 183:4432-4439.
7. Cavelti-Weder C., Babians-Brunner A., Keller C., Stahel M.A., Kurz-Levin M., Zayed H., Solinger A.M., Mandrup-Poulsen T., Dinarello C.A., Donath M.Y. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012, 35:1654-1662.
8. Croxtall J.D. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011, 71:1733-1753.
9. Dinarello C.A. The many worlds of reducing interleukin-1. Arthritis Rheum. 2005, 52:1960-1967.
10. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27:519-550.
11. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
12. Ehses J.A., Lacraz G., Giroix M.H., Schmidlin F., Coulaud J., Kassis N., Irminger J.C., Kergoat M., Portha B., Homo-Delarche F., Donath M.Y. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13998-14003.
13. Ellingsgaard H., Hauselmann I., Schuler B., Habib A.M., Baggio L.L., Meier D.T., Eppler E., Bouzakri K., Wueest S., Muller Y.D., Hansen A.M., Reinecke M., Konrad D., Gassmann M., Reimann F., Halban P.A., Gromada J., Drucker D.J., Gribble F.M., Ehses J.A., Donath M.Y. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17:1481-1489.
14. Elliott M., Benson J., Blank M., Brodmerkel C., Baker D., Sharples K.R., Szapary P. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann. N. Y. Acad. Sci. 2009, 1182:97-110.
15. Emamaullee J.A., Davis J., Merani S., Toso C., Elliott J.F., Thiesen A., Shapiro A.M. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58:1302-1311.
16. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., Nano R., Olek S., Maffi P., Scavini M., Secchi A., Staudacher C., Bonifacio E., Battaglia M. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
17. Fujihira K., Nagata M., Moriyama H., Yasuda H., Arisawa K., Nakayama M., Maeda S., Kasuga M., Okumura K., Yagita H., Yokono K. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 2000, 49:1998-2006.
18. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
19. Hingorani A.D., Casas J.P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet 2012, 379:1214-1224.
20. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., Knip M., Otonkoski T., Vaarala O. IL-17 immunity in human type 1 diabetes. J. Immunol. 2010, 185:1959-1967.
21. Joseph J., Bittner S., Kaiser F.M., Wiendl H., Kissler S. IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. J. Immunol. 2012, 188:216-221.
22. Keymeulen B., Walter M., Mathieu C., Kaufman L., Gorus F., Hilbrands R., Vandemeulebroucke E., Van d., Crenier V.L., De B.C., Candon S., Waldmann H., Ziegler A.G., Chatenoud L., Pipeleers D. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010, 53:614-623.
23. Korn T., Mitsdoerffer M., Croxford A.L., Awasthi A., Dardalhon V.A., Galileos G., Vollmar P., Stritesky G.L., Kaplan M.H., Waisman A., Kuchroo V.K., Oukka M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18460-18465.
24. Lal G., Zhang N., van der Touw W., Ding Y., Ju W., Bottinger E.P., Reid S.P., Levy D.E., Bromberg J.S. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 2009, 182:259-273.
25. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., Mandrup-Poulsen T., Donath M.Y. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007, 356:1517-1526.
26. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., Li S., Dooley L.T., Gordon K.B. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
27. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996, 39:1005-1029.
28. Mandrup-Poulsen T., Bendtzen K., Dinarello C.A., Nerup J. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J. Immunol. 1987, 139:4077-4082.
29. Mandrup-Poulsen T., Pickersgill L., Donath M.Y. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2010, 6:158-166.
30. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 2009, 27:229-265.
31. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., Xu L., Priatel J.J., Levings M.K., Tan R. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 2010, 185:3814-3818.
32. Mastrandrea L., Yu J., Behrens T., Buchlis J., Albini C., Fourtner S., Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32:1244-1249.
33. Murakami M., Nishimoto N. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective. Curr. Opin. Rheumatol. 2011, 23:273-277.
34. Nicoletti F., Di M.R., Zaccone P., Magro G., Di M.M., Grasso S., Meroni P.L. Endogenous interleukin-12 only plays a key pathogenetic role in non-obese diabetic mouse diabetes during the very early stages of the disease. Immunology 1999, 97:367-370.
35. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Marks J.B., Monzavi R., Moran A., Raskin P., Rodriguez H., Russell W.E., Schatz D., Wherrett D., Wilson D.M., Krischer J.P., Skyler J.S. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
36. Oslowski C.M., Hara T., O'Sullivan-Murphy B., Kanekura K., Lu S., Hara M., Ishigaki S., Zhu L.J., Hayashi E., Hui S.T., Greiner D., Kaufman R.J., Bortell R., Urano F. Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab. 2012, 16:265-273.
37. Papp K.A., Langley R.G., Lebwohl M., Krueger G.G., Szapary P., Yeilding N., Guzzo C., Hsu M.C., Wang Y., Li S., Dooley L.T., Reich K. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
38. Pescovitz D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
39. Rose-John S., Waetzig G.H., Scheller J., Grotzinger J., Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 2007, 11:613-624.
40. Rothe H., O'Hara R.M., Martin S., Kolb H. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia 1997, 40:641-646.
41. Sakata M., Yasuda H., Moriyama H., Yamada K., Kotani R., Kurohara M., Okumachi Y., Kishi M., Arai T., Hara K., Hamada H., Yokono K., Nagata M. Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules. Diabetes Res. Clin. Pract. 2008, 80:352-359.
42. Samson M., Audia S., Janikashvili N., Ciudad M., Trad M., Fraszczak J., Ornetti P., Maillefert J.F., Miossec P., Bonnotte B. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64:2499-2503.
43. Sandborn W.J., Gasink C., Gao L.L., Blank M.A., Johanns J., Guzzo C., Sands B.E., Hanauer S.B., Targan S., Rutgeerts P., Ghosh S., de Villiers W.J., Panaccione R., Greenberg G., Schreiber S., Lichtiger S., Feagan B.G. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 2012, 367:1519-1528.
44. Schneider A., Rieck M., Sanda S., Pihoker C., Greenbaum C., Buckner J.H. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J. Immunol. 2008, 181:7350-7355.
45. Schultz O., Oberhauser F., Saech J., Rubbert-Roth A., Hahn M., Krone W., Laudes M. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010, 5:e14328.
46. Suarez-Farinas M., Li K., Fuentes-Duculan J., Hayden K., Brodmerkel C., Krueger J.G. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J. Invest. Dermatol. 2012, 132:2552-2564.
47. Sumpter K.M., Adhikari S., Grishman E.K., White P.C. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr. Diabetes 2011, 12:656-667.
48. Sun M., Fink P.J. A new class of reverse signaling costimulators belongs to the TNF family. J. Immunol. 2007, 179:4307-4312.
49. Sutherland A.P., Van B.T., Wurster A.L., Suto A., Michaud M., Zhang D., Grusby M.J., von Herrath M. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009, 58:1144-1155.
50. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 2012, 52:199-219.
51. Trembleau S., Penna G., Bosi E., Mortara A., Gately M.K., Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J. Exp. Med. 1995, 181:817-821.
52. Trembleau S., Penna G., Gregori S., Gately M.K., Adorini L. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur. J. Immunol. 1997, 27:2330-2339.
53. Trembleau S., Penna G., Gregori S., Giarratana N., Adorini L. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. J. Immunol. 2003, 170:5491-5501.
54. Vendrame F., Pileggi A., Laughlin E., Allende G., Martin-Pagola A., Molano R.D., Diamantopoulos S., Standifer N., Geubtner K., Falk B.A., Ichii H., Takahashi H., Snowhite I., Chen Z., Mendez A., Chen L., Sageshima J., Ruiz P., Ciancio G., Ricordi C., Reijonen H., Nepom G.T., Burke G.W., Pugliese A. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010, 59:947-957.
55. Yasuda H., Nagata M., Arisawa K., Yoshida R., Fujihira K., Okamoto N., Moriyama H., Miki M., Saito I., Hamada H., Yokono K., Kasuga M. Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J. Clin. Invest. 1998, 102:1807-1814.
56. Zaghi D., Krueger G.G., Callis D.K. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J. Drugs Dermatol. 2012, 11:160-167.
57. Zhang J., Huang Z., Sun R., Tian Z., Wei H. IFN-gamma induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice. J. Autoimmun. 2012, 38:20-28.
58. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010, 11:136-140.
59. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., Nakayama M., Rosenthal W., Bluestone J.A. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009, 10:1000-1007.
60. Schneider A., Long S.A., Cerosaletti K., Ni C.T., Samuels P., Kita M., Buckner J.H. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive Tregs involves IL-6-mediated signaling. Sci. Transl. Med. 2013, 5(170).